A prospective study of febrile neutropenia in lung cancer patients by Berghmans, Thierry et al.
38
HOSPITAL CHRONICLES 2(1), 2007
A prospective study of febrile neutropenia 
in lung cancer patients
Thierry Berghmans, Anne-Pascale Meert and Jean-Paul Sculier
A B S T R A C T
BACKGROUND There are few data on microbiology of febrile neutropenia (FN) in 
lung cancer patients. The primary objective of this study was to evaluate the epidemi-
ology of FN in this population.
PATIENTS AND METHODS All patients with lung cancer treated with chemotherapy in 
the Institut Jules Bordet (a cancer hospital) and who developed FN (PMN <500/mm³) 
were included in the present prospective study. Febrile neutropenia was defined as 
any febrile episode (38.5°C once or 38.0°C twice) occurring during neutropenia (neu-
trophil count <500/mm³).
RESULTS Ninety five patients, 62 with non-small cell and 33 with small cell lung car-
cinoma developed FN. A total of 102 FN episodes were observed. Of these, 46 were 
microbiologically and 14 clinically documented. The most frequent site of infection 
was the lung (31%). Gram-negative bacteria, mainly Escherichia coli and Haemophi-
lus influenzae, were most commonly observed. In bacteremic patients, Gram-positive 
bacteria, essentially Streptococcus sp, Enterococcus sp and Staphylococcus aureus, 
accounted for 39% of the micro-organisms.
CONCLUSION Lung constitutes the predominant site of infection in febrile neutro-
penic lung cancer patients. In these patients, E. coli and H. influenzae are the most 
commonly documented pathogens, except in case of bacteremia where Streptococcus 
sp and S. aureus as well as E. coli are the principal pathogens.
I N T R O D U C T I O N
Infection is one of the commonest complications associated with cancer. Differ-
ent factors are contributing: immunosuppression related to cancer or its treatment, 
visceral neoplastic obstruction, use of implantable devices and invasive procedures, 
disruption of physiological barriers or blood product transfusion [1]. In lung cancer 
patients neutropenia, chronic obstructive bronchopulmonary disease (COPD) and 
bronchial obstruction are probably the main causes favouring infection. Epidemiologi-
cal data on infections in lung cancer patients are scarce. We have previously reported 
a prospective epidemiological study demonstrating that the majority of lung infections 
were predominantly due to Gram negative bacteria [2]. Few other studies have assessed 
the respective frequency of the infection types and microbiology in these patients, 
also demonstrating that infections occur essentially in the lung.
Chemotherapy is now generally accepted as part of the treatment of patients 
with lung cancer, whatever stage or histology are considered [3-5]. Chemotherapy is 
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frequently associated with intermittent neutropenia, a factor 
well known to predispose to infection. Data specifically col-
lected in patients with lung cancer are rare. In small cell lung 
carcinoma (SCLC), febrile neutropenia (FN) occurred in 18% 
to 77% of the chemotherapeutic cycles [6-9] or in 23% of the 
patients [10]. In non small cell lung carcinoma (NSCLC), up 
to 6% of the patients will develop FN during chemotherapy 
[11,12]. Those data were extracted from clinical trials assess-
ing the role of chemotherapy in selected groups of patients. 
To our knowledge, only one study assessed both the type of 
infection and the microbiological nature of FN in patients with 
lung cancer. This is a retrospective analysis of a randomised 
study with primary endpoint the route of administration of 
empiric antibiotic therapy in FN. In this Japanese study, 35 
patients developed 42 FN episodes, of which two thirds were 
fever of unknown origin (FuO) [13]. Among 15 documented 
infections, 10 originated in the lung.
The primary objective of our study was to determine the 
infection types and the microbiology of febrile neutropenia 
and the secondary objective to estimate its frequency in an 
unselected population of NSCLC and SCLC patients treated 
with conventional chemotherapy in a specific single centre 
cancer hospital.
P A T I E N T S  A N D  M E T H O D S
All lung cancer patients hospitalized in the Critical care 
Department or the Thoracic Oncology unit of our cancer 
hospital were prospectively registered in this study at the time 
febrile neutropenia occurred. Febrile neutropenia was defined 
as any febrile episode (38.5°C once or 38.0°C twice) occurring 
during neutropenia (neutrophil count <500/mm³). The data 
collected by the physicians in charge of the lung cancer patients 
was based on results provided by the microbiology laboratory 
and the infectious disease consultant. Specific data on some 
risk factors have been added: corticosteroid treatment, central 
or peripheral venous catheters, pleural or bladder catheters, 
mechanical ventilation, tracheotomy, and COPD. Cultures 
of blood, sputum, and urine as well as nose, mouth and anal 
swabs were systematically performed in addition to sampling 
from the suspected infectious site, if any.
Microbiologically and clinically documented infections 
were both considered. When the patient was presented with 
fever non responding to empiric antibiotic therapy without 
known site of infection or other etiology of the fever, such 
as drug, blood products transfusions and paraneoplastic fe-
vers, the episode was classified as a fever of unknown origin 
(FuO).
Collection of urine, sputum and stool samples was per-
formed according to standard procedures. Simple aspiration 
or bronchoalveolar lavage could be done during bronchoscopy. 
Protected sampling was not performed. Blood cultures were 
performed in duplicate, using the aerobic and anaerobic 
BactecR systems. Cultures were performed according to the 
routine procedures of the hospital laboratory. Bacteremia 
or fungemia were diagnosed when a potentially pathogenic 
organism was found in the blood culture. Coagulase-negative 
Staphylococcus or Corynebacterium were characterized as 
pathogens when they were isolated in more than one culture, 
from the blood plus a distinct clinically infected site, or from 
a clinically septic patient with an intravascular device. A 
positive urinary culture was considered as significant in the 
presence of focal (dysuria, polyuria) or systemic signs of infec-
tion. Tracheal secretion aspirations in intubated patients and 
sputum or tracheal aspirations in non-intubated patients were 
considered as positive if associated with clinical or radiological 
signs compatible with infection. Ear, nose, and throat (ENT) 
infections were considered significant when local signs of 
clinical infection were detected and a potential pathogen was 
simultaneously isolated from the mouth, the nose, the throat 
or the sinuses. Every effort was made to differentiate infec-
tion from colonization [14]. Clinically documented infections, 
principally when affecting the tracheobronchial tree and the 
skin, were considered significant if clinical or radiological 
signs were compatible with the diagnosis of infection as well 
as the evolution on empiric antibiotic therapy, and no other 
etiology could be identified. Superinfection was defined as a 
new infection that occurred during the 7 days following the 
completion of antibiotic therapy for the initial episode.
Binary variables were compared by chi square tests. A p 
value <0.05 was considered as statistically significant. All sta-
tistical tests were performed using the StatisticaR software.
R E S U L T S
PA T I E N T S  C H A R A C T E R I S T I C S
From 02/1997 to 12/2005, 1064 patients with NSCLC, 
SCLC or mesothelioma were followed in the clinic of Thoracic 
Oncology of our hospital. Among them, 776 patients received 
chemotherapy. The neoplastic disease was NSCLC in 637, 
SCLC in 127 and malignant pleural mesothelioma in 12. Dur-
ing this period, 95 patients developed 102 distinct episodes of 
febrile neutropenia. Some of them were included in a previ-
ous publication on infections in lung cancer patients [2]. The 
principal characteristics of the febrile neutropenic patients 
with NSCLC and SCLC are presented in Table 1.
The following comorbidities and/or potentially predispos-
ing conditions were present at the diagnosis of the infectious 
episodes: COPD (n=19), corticosteroid therapy (n=13), 
peripheral venous catheter (n=20), central (n=4) or totally 
implantable venous catheters (n=18) and bladder catheter 
(n=3). Only two patients received G-CSF at the time of FN. 
Prophylactic antibiotics were not prescribed. Sixty-four per-
cent of the infections occurred either at home (n=59) or were 
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acquired within 48 hours after hospital admission (n=6). For 
patients hospitalized at the time of the infection, the median 
hospital stay before occurrence of febrile neutropenia was 
10 days.
T y P E S  O f  I N f E C T I O N  A N D  M I C R O B I O L O G I C A L 
R E S U L T S
Bacteremia or fungemia were documented in 18 cases 
(17.6% of all infectious episodes) of which 5 were of primary 
origin. The most frequent site of infection was the lung with 
24 non-bacteremic and 8 bacteremic episodes. Other sites of 
infections, in decreasing order, were, digestive tract (n=8), 
urinary tract (n=7), head and neck (n=6) and skin (n=2). The 
distribution of infection types according to histology is shown 
in Table 2. Forty-six infections were microbiologically and 14 
were clinically documented, 45% and 14% from the total of 
FN episodes respectively. Fever of unknown origin (FuO) 
was the final diagnosis in 42 cases (41%). Microbiologically 
documented infections accounted for 45% of the FN episodes 
with a total of 56 microorganisms (Table 3).
There were 7 documented polymicrobial infections. The 
most frequent pathogens were Gram-negative bacteria (n=39; 
70%) followed by Gram-positive bacteria (n=13; 23%), fungi 
(n=2; 4%) and viruses (n=2; 4%). The four most frequent 
Gram-negative bacteria were Escherichia coli (n=13), Hae-
mophilus influenzae (n=9), Moraxella catarrhalis (n=3) and 
Pseudomonas aeruginosa (n=3). Streptococcus sp. (n=3), 
Enterococcus sp (n=4) and Staphylococcus aureus (n=4) con-
stituted the main Gram-positive bacteria. All fungal infections 
were due to Candida albicans. Two Herpes simplex cases were 
documented. When only pathogens documented in blood cul-
tures were considered, Gram positive bacteria were observed 
more often (Table 4). unexpected resistance to conventional 
antibiotics was infrequently found. None of the Staphylococcus 
aureus strains were resistant to methicillin. One Acinetobacter 
baumanii was considered as a multiresistant bacteria.
Infections resolved in 93 cases (91.2%). One episode was 
not assessable for response due to a lack of follow-up. The 
last 8 patients died from or during their febrile neutropenia, 
between less than 1 day and 13 days after the occurrence of 
the febrile episode. Those were four NSCLC (3 stage Iv and 
one stage IIIB) and 4 SCLC (1 limited and three metastatic 
diseases) patients. Infection occurred at home in 5 cases. All 
presented with microbiologically or clinically documented 
infections except one FuO: pneumonia with (n=4) or without 
(n=1) bacteremia, fungemia (n=1) and typhlitis (n=1). Eight 
pathogens were documented: Escherichia coli, Pseudomo-
nas aeruginosa, Klebsiella oxytoca, Acinetobacter baumanii, 
Enterobacter aerogenes, Staphylococcus aureus, Clostridium 
difficile and Candida albicans. Three bacteria were resistant 
to the initial antibiotic therapy, including the multiresistant 
Acinetobacter baumanii.
There were 11 superinfections. They included lung infec-
tions (n=3), soft tissue infection (n=1), mucositis (n=3), and 
TABLE 1. Characteristics of the 95 febrile neutropenic 
patients with NSCLC or SCLC.
Non-small cell 
lung cancer
Small cell lung 
cancer
Number of patients 62 33
Age: median (range) 62 years (37-83) 66 years (43-77)
Gender: male/female 45/17 20/13
Stage II 2
IIIA 7
IIIB 10
Iv 43
Limited disease 8
Extensive disease 25
TABLE 2. Infection types according to tumour histology
Infection types Non-small cell lung cancer
(63 infectious episodes among 62 patients)
Small cell lung cancer
(39 infectious episodes among 33 patients)
Bacteriemia 11
Primary origin 2
Lung 6
Digestive tract 1
urinary 1
Skin 1
7
Primary origin 3
Lung 2
urinary 2
Lung 21 (including 6 bacteriemia) 11 (including 2 bacteriemia)
Digestive tract 6 (including one bacteriemia) 2
urinary tract 1 (corresponding to a bacteriemia) 6 (including 2 bacteriemia)
Head and neck 4 2
Skin 2 (including one bacteriemia) -
Fever of unknown origin 27 15
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Among those patients presenting with FN, we looked for 
a possible association with clinical characteristics. Cortico-
steroid administration was not predictive of poorer outcome 
(16.7% versus 6.7%; odds ratio (OR)=2.5; p=0.24) and it was 
also not associated with an increased risk of superinfection 
(15.4% versus 10.1%; OR=1.52; p=0.63). Bacteremia was 
associated with catheter use (28.6% versus 10.0%; OR=2.86; 
p=0.02). A statistically significant association between 
COPD and lung infection was observed (52.6% versus 26.5%; 
OR=1.99; p=0.03). FuO occurred at the same frequency 
at home or during hospitalization (64.3% versus 53.3%; 
OR=1.21; p=0.27).
D I S C U S S I O N
In this prospective study, we found that the principal site 
of infection in lung cancer patients was the lung. Among 
bacteremic episodes, lung accounted for 44% of the primary 
sites. Gram negative bacteria, mainly Escherichia coli and 
Haemophilus influenzae, predominated except in case of 
bacteremia where Gram positive bacteria were documented 
in 43% of the cases.
The aim of this study was to more precisely delineate the 
infection sites and nature of the responsible pathogens in 
lung cancer patients with febrile neutropenia. Few data are 
available on this topic. For the majority, they were extracted 
from retrospective analyses of prospective clinical trials as-
sessing chemotherapy in SCLC or NSCLC [6-8,10-12]. In these 
studies, only the frequency of FN was documented. To our 
knowledge, only one Japanese study addressed retrospectively 
the question of site and microbiological nature of FN in lung 
cancer [13]. FuO was observed in two thirds of our cases and 
infection originated in the lung in the majority of the docu-
TABLE 3. Documented pathogens according to tumour 
histology.
Pathogens Non-small 
cell lung 
cancer
Small 
cell 
lung 
cancer
Total
Gram-positive bacteria 7 6 13
Streptococcus sp 2 1 3
Enterococcus sp 2 2 4
Staphylococcus aureus 2 2 4
Bacillus sp. - 1 1
Clostridium difficile 1 - 1
Gram-negative bacteria 25 14 39
Escherichia coli 4 9 13
Haemophilus influenzae 8 1 9
Moraxella catarrhalis 2 1 3
Pseudomonas aeruginosa 3 - 3
Klebsiella sp 2 - 2
Acinetobacter sp - 2 2
Other Gram negative bacteria 6 1 7
Other pathogens 4
Candida albicans - 2 2
Herpes simplex - 2 2
Total 32 24 56
TABLE 4. Documented pathogens in positive blood cultures (n=18 bacteremic episodes)
Original site of infection
Pathogens Pulmonary Urinary Skin Digestive Not identified Total
Streptococcus sp 1 - - - 1 2
Enterococcus sp 1 3 4
Staphylococcus aureus 3 - - - - 3
Bacillus sp. 1 - - - - 1
Escherichia coli - 3 1 - 2 6
Klebsiella sp 2 - - - - 2
Pseudomonas aeruginosa 1 - 1 - - 2
Acinetobacter baumanii 1 - - - - 1
vibrio non cholerae - - - 1 - 1
Candida albicans - - - - 1 1
Total 10 3 2 1 7 23
bacteremia, colitis, sinusitis and FuO one case each. Nine 
microorganisms were documented Xanthomonas maltophilia 
(n=2), Clostridium difficile, Staphylococcus aureus, Candida 
albicans, Candida glabrata and Aspergillus fumigatus in one 
case each and two Herpes simplex I.
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C O N C L U S I O N S
In conclusion, we have demonstrated that most of the 
documented febrile episodes in neutropenic lung cancer pa-
tients originated from lung. Gram-negative bacteria, mainly 
Escherichia coli and Haemophilus influenzae, were the pre-
dominant microorganisms except in case of bacteremia, where 
Gram-positive bacteria were more often documented. We did 
not observe a higher rate of resistance to conventional antibiot-
ics than it was expected. In lung cancer patients with febrile 
neutropenia, the guidelines proposed by the IDSA should be 
applied. Broad spectrum  lactams or carbapenems can be 
suggested as first-line therapy. Oral antibiotic therapy should 
be considered in low risk patients.
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reported, confirms that lung is the primary site of infection 
in most patients. We made the same observation in a previ-
ous study assessing infection in an unselected population of 
patients with lung cancer [2]. The high prevalence of lung as 
the primary site of infection, as it is suggested in our present 
and previous study, may be related to frequent existence of 
concomitant COPD, which is known to predispose to lung 
infections as well as to neoplastic obstruction.
We found that the predominant pathogens, in this popula-
tion not receiving antibiotic prophylaxis, were Gram-negative 
bacteria except for bacteremia where Gram-positive bacteria 
were documented in 2/5 of the cases. This observation is well in 
accordance with observations in the recent literature in various 
cancer populations [15], where up to 60% of the microbiologi-
cally documented FN episodes were due to Gram-negative 
bacteria. Among those, Escherichia coli was the commonest 
pathogen, as it was observed in our study. Nevertheless, in our 
population of lung cancer patients, we found that Haemophilus 
influenzae was nearly as common as E. coli. This is not surpris-
ing as we made the same observation in a previous study [2] and 
because H. influenzae is a common lung or bronchial pathogen 
in COPD patients. Interestingly, we found that Streptococcus 
sp, Enterococcus sp and Staphylococcus aureus accounted re-
spectively for 8.7%, 17.4% and 13.0% of the microorganisms 
documented in case of bacteriemia. An increasing frequency 
of Streptococcus sp, principally of the viridans group, and 
Enterococcus sp was reported in FN patients [15]. However, 
the increase in Gram-positive bacteremia was also due to 
coagulase-negative Staphylococci that were not documented 
in our study. This could be explained by the low rate of totally 
implantable catheters used in our daily practice, a main risk 
factor for bacteremia as it was found in our study.
Our observation has direct implications in clinical practice. 
As with FN occurring in other cancer populations, broad spec-
trum antibiotics must be administered in lung cancer patients 
on an empirical basis. Guidelines have been published by the 
Infectious Disease Society of America (IDSA) for the use of 
antimicrobials in patients with cancer and FN [16]. Outside of 
local epidemiology, broad spectrum  lactams or carbapenems 
are suggested as first-line therapy while glycopeptides must 
be administered only in case of documented resistant Gram-
positive infection or clinical signs suggesting infection with 
resistant Gram-positive organisms. Oral antibiotic therapy 
should be considered for low risk patients. The role of new 
fluoroquinolones with increased activity against Gram-posi-
tive pathogens remains to be validated in randomised trials. 
According to the type and microbiological nature of infections 
and the drug-sensitivity pattern observed in our study, we 
suggest to use the recommendations of the IDSA in febrile 
neutropenic lung cancer patients.
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